|
RICHMOND, Va. — Delegate Karrie Delaney (D-Fairfax) today announced she has filed HB1724 to create a Prescription Drug Affordability Board. Del. Delaney rolled out the bill alongside Delegate Nadarius Clark (D-Suffolk), Delegate Ellen Campbell (R-Rockbridge), Senator-elect Kannan Srinivasan (D-Loudoun), AARP Virginia, Freedom Virginia, and impacted Virginians.
Prescription Drug Affordability Board legislation gained bipartisan momentum during the 2024 General Assembly session when bills from the House and Senate passed through each chamber with bipartisan support and reached the governor’s desk, where they were vetoed.
The Prescription Drug Affordability Board would be an independent body of health and medical experts that will lower the cost of medicine by creating upper payment limits on how much Virginia consumers will pay for certain high-cost medications. PDABs have been established under both Republican and Democratic administrations across eight states, including most recently in Minnesota and Colorado.
As a result of federal action, seniors who rely on Medicare are already seeing benefits with the 2023 $35 a month cap on insulin and a $2,000 annual cap on total out-of-pocket costs beginning this month. In 2026, more than 150,000 Virginians who rely on Medicare will see savings benefits as a result of Medicare price negotiations on ten high-cost prescription drugs. However, there are more than 7 million Virginians not on Medicare who would benefit from the cost savings of a PDAB.
A 2023 poll from AARP found that three-quarters of Virginia voters want their legislators to pass a PDAB, including 85% of Democrats, 71% of Republicans, and 70% of Independents.
Find highlights from the conference below
“No one should have to choose between taking the medicine they need and keeping food on the table or a roof over their head,” said AARP Virginia State Advocacy Director Jared Calfee. “A Prescription Drug Affordability Board will protect consumers here in Virginia from dangerous price-gouging practices and help address the cost of some of the most expensive drugs on the market that treat life-threatening illnesses.”
|